Rehmann Capital Advisory Group Has $330,000 Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Rehmann Capital Advisory Group decreased its position in DexCom, Inc. (NASDAQ:DXCM) by 4.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,381 shares of the medical device company’s stock after selling 99 shares during the quarter. Rehmann Capital Advisory Group’s holdings in DexCom were worth $330,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. DSM Capital Partners LLC bought a new stake in shares of DexCom in the 4th quarter worth $28,000. Riverview Trust Co bought a new stake in shares of DexCom in the 1st quarter worth $32,000. Valley National Advisers Inc. grew its stake in shares of DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after acquiring an additional 103 shares in the last quarter. MV Capital Management Inc. grew its stake in shares of DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after acquiring an additional 138 shares in the last quarter. Finally, Smithfield Trust Co grew its stake in shares of DexCom by 103.1% in the 4th quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after acquiring an additional 165 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. UBS Group increased their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Canaccord Genuity Group increased their price target on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Citigroup increased their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Raymond James increased their target price on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday, April 26th. Finally, StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $140.33.

Insider Buying and Selling

In related news, Director Bridgette P. Heller sold 1,000 shares of DexCom stock in a transaction on Friday, June 14th. The shares were sold at an average price of $113.55, for a total value of $113,550.00. Following the transaction, the director now directly owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other DexCom news, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the transaction, the director now directly owns 25,349 shares of the company’s stock, valued at approximately $2,878,378.95. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the transaction, the executive vice president now directly owns 42,377 shares in the company, valued at $5,839,974.37. The disclosure for this sale can be found here. Insiders have sold a total of 6,102 shares of company stock valued at $755,103 over the last three months. 0.30% of the stock is owned by company insiders.

DexCom Trading Down 0.2 %

Shares of NASDAQ DXCM traded down $0.17 during mid-day trading on Wednesday, hitting $110.67. The stock had a trading volume of 1,283,211 shares, compared to its average volume of 2,888,789. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00. The business has a 50 day moving average price of $120.40 and a two-hundred day moving average price of $125.22. The firm has a market cap of $44.01 billion, a P/E ratio of 71.61, a price-to-earnings-growth ratio of 2.71 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The company had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. On average, equities analysts anticipate that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.